Monthly Archives: February 2014

Biothera Presents Phase 2 Data to International Association for the Study of Lung Cancer

EAGAN, MN — February 24, 2014 — Biothera presented results of its Phase 2b clinical trial in non-small cell lung cancer (NSCLC) this past weekend to top clinicians and scientists at the invitation-only International Association for the Study of Lung Cancer meeting on targeted therapies in Santa Monica, CA. Biothera’s Imprime PGG® is a Phase 3 cancer immunotherapy drug that engages and directs immune cells...

Read More


Bruce L.A. Carter Ph.D. Joins Biothera Board of Directors

EAGAN, MN — February 5, 2014 — Biothera announced today the appointment of Bruce L.A. Carter, Ph.D. to its board of directors. “Dr. Carter’s scientific expertise and executive management experience, particularly in pharmaceutical strategy and M&A, will be invaluable to Biothera,” said Dan Conners, Biothera chairman of the board. “I’ve been in this industry a long time and I’m excited about Biothera’s truly novel approach...

Read More


Biothera to Present at IASLC Meeting on Targeted Lung Cancer Therapies

EAGAN, MN — February 3, 2014 — Biothera has been selected to present its clinical results at the 14th Annual Targeted Therapies for the Treatment of Lung Cancer Meeting February 19-22 in Santa Monica, CA. The meeting is sponsored by the International Association for the Study of Lung Cancer. The invitation-only meeting gathers the top clinicians and scientists to discuss the latest advances in the...

Read More